Teva Pharmaceutical Industries Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard D. Francis
- Full Time Employees
- 37,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 124 Dvora Hanevi'a Street Tel Aviv TA Israel 6944020
- IPO Date
- Feb 16, 1982
- CIK
- 0000818686
- Website
- tevapharm.com
- Similar Companies
- Business
- Teva Pharmaceutical Industries Limited, an Israeli multinational pharmaceutical company founded in 1901 and headquartered in Petah Tikva, Israel, develops, manufactures, markets and distributes generic medicines, innovative branded drugs, biopharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products worldwide across more than 60 countries with manufacturing facilities in Israel, North America, Europe, Australia and South America; core generic offerings span various dosage forms including tablets, capsules, ointments, creams, liquids, injectables and inhalants for therapeutic areas such as pain management, cardiovascular diseases, infectious diseases, central nervous system disorders, respiratory conditions, oncology and generics leadership in complex products; key innovative medicines include AUSTEDO (deutetrabenazine) for chorea in Huntington's disease and tardive dyskinesia, AJOVY (fremanezumab) for migraine prevention, UZEDY for schizophrenia, Copaxone for multiple sclerosis and a pipeline featuring olanzapine LAI, duvakitug for inflammatory bowel disease, DARI asthma inhaler, emrusolmin and TEV-56278 (anti-PD1-IL2 ATTENUKINE) for oncology. The company operates in segments including generics and biosimilars targeting healthcare providers, pharmacies and hospitals globally, with a focus on neuroscience, immunology, respiratory diseases and pain management customer bases. Teva advances its Pivot to Growth strategy, launched in 2023 and accelerated in 2025, to build a greater than $5 billion innovative medicines franchise by 2030 through robust late-stage pipeline execution, 25 to 27 biosimilar launches by 2027 including eculizumab-aagh with Samsung Bioepis and PONLIMSI/DEGEVMA denosumab biosimilars approved in Europe; recent strategic partnerships encompass a June 2025 collaboration with Fosun Pharma for TEV-56278 development in Asia, a prior alliance with Sanofi for TEV-574 anti-TL1A in inflammatory bowel disease, and the November 2025 launch of Teva Rise open innovation platform for AI, digital health and manufacturing advancements; ongoing efforts include divestiture of its API business TAPI announced in 2024, eleven consecutive quarters of revenue growth as of Q3 2025 driven by 33% innovative portfolio increase in local currency, reaffirmed 2027 targets of 30% operating profit margin, over $2.7 billion free cash flow and $2.5 billion Estero revenues with peak sales exceeding $3 billion, alongside credit upgrades reflecting debt reduction and operational enhancements.
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?
Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Bill Ackman Says Next $1 Trillion Company Will Come From Israel – ‘Imagine if Silicon Valley Was a Country'
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript